-
Have your staff members' shellac nails raised questions about whether they are artificial and an infection control threat?
-
After a talk I gave last month, someone came up to me after the meeting and asked me this question, "After all the years you have been doing this [surgical consulting], what are some of the things you have learned?"
-
Atrial fibrillation (AF) is an irregular, disorganized, electrical activity of the atria.1 It is characterized by uncoordinated atrial activity that leads to inefficient atrial contraction and impaired ventricular filling, which leads to hemodynamic and mechanical functional impairments.
-
Abdominal pain with vomiting is a common presenting complaint to the emergency department (ED) in infants. In the majority of cases, the patient's symptoms come from a benign cause such as gastroenteritis. However, it remains essential for the emergency physician (EP) to thoroughly understand the differential diagnosis of abdominal pain and vomiting in infants, particularly identifying those causes requiring surgical intervention.
-
It has been customary to ask patients on warfarin, once controlled and stable, to return on a monthly basis for recheck.
-
The authors conclude that in a population-based cohort undergoing 4 years of follow-up, the prevalence of diastolic dysfunction increased and that diastolic dysfunction was associated with development of heart failure during 6 years of subsequent follow-up.
-
Sleep-disordered breathing is a significant risk factor for cognitive decline and continuous positive airway pressure (CPAP) therapy may prevent or slow this process.
-
Duplex ultrasonography should be used in asymptomatic patients with known or suspected carotid arterial stenosis and should be considered for use in asymptomatic patients who have symptomatic peripheral arterial disease, coronary artery disease, or an atherosclerotic aortic aneurysm, and even in the asymptomatic patients who simply are at high cardiovascular risk.
-
An ultra long-acting, orally-inhaled beta2-adrenergic agonist (LABA) has been approved for the treatment of chronic obstructive pulmonary disease (COPD). Indacaterol is formulated as a dry powder and is the first beta2-agonist to be dosed once-daily. It is marketed by Novartis as Arcapta™.
-